Immunoisolation device
US-2018318360-A1 · Nov 8, 2018 · US
US11312950B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11312950-B2 |
| Application number | US-201815895710-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 13, 2018 |
| Priority date | Feb 16, 2017 |
| Publication date | Apr 26, 2022 |
| Grant date | Apr 26, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method to prepare synthetic hydrogels having tissue-specific properties, and a hydrogel comprising a polymer matrix comprising a plurality of peptide, are provided.
Opening claim text (preview).
What is claimed is: 1. A hydrogel comprising a polymer matrix comprising a plurality of peptides, wherein one of the peptides comprises VTCG (SEQ ID NO:26) and another peptide comprises LRE and the hydrogel optionally includes peptides from two or more of entactin/nidogen; vitronectin; vWF; netrin 1; fibronectin; collagen 1; fibrinogen alpha; osteopontin; fibrinogen gamma; thrombospondin; collagen IX; tenascin C; laminin-alpha; laminin-beta; laminin gamma; MMP-1, MMP-14, MMP-2, MMP-3, MMP-7, MMP-9, or MMP-13, wherein the peptide comprising LRE in the hydrogel is about 1% to about 2% and the peptide comprising VTCG (SEQ ID NO:26) is about 4% to about 6%. 2. The hydrogel of claim 1 wherein the peptides further include one or more of peptides comprising RGD, YIGSR (SEQ ID NO: 22), IKVAV (SEQ ID NO: 23), AEIDGIEL (SEQ ID NO: 24), DGEA (SEQ ID NO: 25), YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 27), SVVYLR (SEQ ID NO: 28), GPR, GFXaaGER (SEQ ID NO: 74), PHSRN(G)6RGD (SEQ ID NO: 73), or QWRDTWARRLRICFQQREKKGKCRKA (SEQ ID NO: 31). 3. The hydrogel of claim 2 , wherein the peptide comprising RGD is about 25% to about 35%, comprising YIGSR (SEQ ID NO: 22) is about 1% to about 3%, comprising IKVAV (SEQ ID NO: 23) is about 2% to about 4%, comprising AEIDGIEL (SEQ ID NO: 24) is about 2% to about 4%, comprising DGEA (SEQ ID NO: 25) is about 2% to about 4%, the YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 27) is about 4% to about 6%, comprising SVVYLR (SEQ ID NO: 28) is about 7% to about 9%, comprising GPR is about 7% to about 9%, comprising GFXaaGER (SEQ ID NO: 74) is about 7% to about 9%, comprising PHSRN(G)6RGD is about 10% to about 12%, or comprising QWRDTWARRLRICFQQREKKGKCRKA (SEQ ID NO: 31) is about 10% to about 12%. 4. The hydrogel of claim 1 wherein the peptides further include one or more peptides comprising VPMSMRGG (SEQ ID NO: 32), SGESPAYYTA (SEQ ID NO: 33), RPFSMIMG (SEQ ID NO: 34), VPLSLTMG (SEQ ID NO: 35), VPLSLYSG (SEQ ID NO: 36), GPLGLWAR (SEQ ID NO: 37), or IPESLRAG (SEQ ID NO: 38). 5. A hydrogel comprising a polymer matrix comprising a plurality of peptides, wherein the peptides comprise VTCG (SEQ ID NO:26) and LRE and one or more of VPMSMRGG (SEQ ID NO: 32), SGESPAYYTA (SEQ ID NO: 33), RPFSMIMG (SEQ ID NO: 34), VPLSLTMG (SEQ ID NO: 35), VPLSLYSG (SEQ ID NO: 36), GPLGLWAR (SEQ ID NO: 37), or IPESLRAG (SEQ ID NO: 38), wherein the VPMSMRGG (SEQ ID NO: 32) is about 15% to about 20%, SGESPAYYTA (SEQ ID NO: 33) is about 15% to about 25%, RPFSMIMG (SEQ ID NO: 34) is about 15% to about 25%, VPLSLTMG (SEQ ID NO: 35) is about 10% to about 20%, VPLSLYSG (SEQ ID NO: 36) is about 5% to about 15%, GPLGLWAR (SEQ ID NO: 37) is about 7% to about 13%, or IPESLRAG (SEQ ID NO: 38) is about 7% to about 13%. 6. The hydrogel of claim 1 , wherein the polymer matrix comprises PEG, agarose, collagen, fibrin, silk, or methylcellulose. 7. The hydrogel of claim 1 wherein the polymer matrix is cross-linked. 8. The hydrogel of claim 1 which has peptides from laminin A/C, laminin β1, laminin γ, fibrinogen α, fibrinogen β, fibrinogen γ, thrombospondin-1, vitronectin, fibronectin, collagen α1, collagen 1, collagen αI, collagen II, collagen III, collagen IV, collagen α21, collagen I, collagen V, collagen IV, vWf, fibrinogen α, fibrinogen β, fibrinogen γ, vitronectin, and/or fibronectin, tenascin R, or Galectin 1. 9. The hydrogel of claim 1 which has peptides from collagen αI, collagen II, collagen III, collagen IV, collagen α21, collagen I, collagen V, collagen IV, vWf, fibrinogen α, fibrinogen β, fibrinogen γ, vitronectin, and/or fibronectin, tenascin R, or Galectin 1. 10. The hydrogel of claim 1 wherein the peptides in the hydrogel further include one or more of IPVSLRSGDRCG (SEQ ID NO:52), RPFSMIMG (SEQ ID NO:34), VPLSLTMG (SEQ ID NO: 35), VPLSLYSG (SEQ ID NO:36), IPESLRAG (SEQ ID NO:38), DGEA (SEQ ID NO:25), IKVAV (SEQ ID NO:23), YIGSR (SEQ ID NO:22), PHSRN-RGD (SEQ ID NO:30), GPR or RGD.
entrapped within the carrier, e.g. gel or hollow fibres · CPC title
Synthetic polymers · CPC title
Substrates of biological origin, e.g. extracellular matrix, decellularised tissue · CPC title
Cellulose or derivatives thereof · CPC title
Agarose, agar-agar · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.